Regulatory framework in Pakistan: situation analysis of medicine quality and future recommendations

References

• Koczwara A, Dressman J. Poor-quality and counterfeit drugs: a systematic assessment of prevalence and risks based on data published from 2007 to 2016. J Pharm Sci. 2017.
   Google Scholar
• Johnston A, Holt DW. Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol. 2014;78(2):218–243.
   PubMed Web of Science ®Google Scholar
• Almuzaini T, Choonara I, Sammons H. Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open. 2013;3(8):e002923.
   PubMed Web of Science ®Google Scholar
• Attaran A, Barry D, Basheer S, Bate R, Benton D, Chauvin J, Garrett L, Kickbusch I, Kohler JC, Midha K, Newton PN, Nishtar S, Orhii P, McKee M. How to achieve international action on falsified and substandard medicines. Br Med J. 2012;345:e7381.
   PubMed Web of Science ®Google Scholar
• Tremblay M. Medicines counterfeiting is a complex problem: a review of key challenges across the supply chain. Curr Drug Saf. 2013;8(1):43–55.
   PubMedGoogle Scholar
• Caudron JM, Ford N, Henkens M, Mace C, Kiddle-Monroe R, Pinel J. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Tropical Med Int Health. 2008;13(8):1062–1072.
   PubMed Web of Science ®Google Scholar
• Shakoor O, Taylor RB, Behrens RH. Assessment of the incidence of substandard drugs in developing countries. Tropical Med Int Health. 1997;2(9):839–845.
   PubMed Web of Science ®Google Scholar
• Rashid H. Impact of drug regulatory authority, Pakistan: an evaluation. New visions of public affairs, vol. 7; 2015. https://cpb-us-w2.wpmucdn.com/sites.udel.edu/dist/a/7158/files/2018/01/nvpa_rashid-1dtzm9j.pdf. Accessed 8 Aug 2018
   Google Scholar
• Senate Secretariat. Drug regulatory Authority of Pakistan act, 2012. Islamabad. The gazette of Pakistan; 2012. http://dra.gov.pk/docs/DRAP%20Act.pdf. Accessed 11 July 2018.
   Google Scholar
• Atif Muhammad, Ahmad Mahmood, Saleem Quratulain, Curley Louise, Qamar-uz-Zaman Muhammad, Babar Zaheer-Ud-Din. Pharmaceutical Policy in Pakistan. In: Zaheer-Ud-Din-Babar, editor. Pharmaceutical Policy in Countries with Developing Healthcare Systems. Switzerland: Springer International Publishing;2017. p.25–44.
   Google Scholar
• Nishtar S. Pharmaceuticals-strategic considerations in health reforms in Pakistan. J Pak Med Assoc. 2006;56(12 Suppl 4):S100–S111.
   PubMedGoogle Scholar
• World Health Organization. WHO Programme for international drug monitoring. Geneva, Switzerland, 2019.https://www.who-umc.org/global-pharmacovigilance/who-programme/. Accessed 2 Feb 2019.
   Google Scholar
• The World Bank. World Bank Country and Lending Groups-Country Classification. Washington, DC 20433 USA. 2018. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519, Accessed 6 Jan 2018.
   Google Scholar
• Pakistan Bureau of Statistics. Monthly bulletin of statistics-September 2017. 2017. http://www.pbs.gov.pk/content/population-census. Accessed 11 Oct 2018.
   Google Scholar
• Pakistan Bureau of Statistics. Population by 5 years age group-Pakistan. 2018. http://www.pbs.gov.pk/content/population-5-year-age-group-pakistan. Accessed 14 Oct 2018.
   Google Scholar
• Finance Division Government of Pakistan. The economic survey of Pakistan 2016—17 chapter: health and nutrition. 2017. http://www.finance.gov.pk/survey/chapters_16/11_Health.pdf. Accessed 16 Oct 2018.
   Google Scholar
• Pakistan Bureau of Statistics. National Health Accounts of Pakistan, 2015—2016. 2018. http://www.pbs.gov.pk/sites/default/files//NHA-Pakistan%202015-16%20Report_0.pdf. Accessed 14 Oct 2018.
   Google Scholar
• World Health Organization. Global Health Observatory country views, Pakistan statistics summary (2002-present). Geneva, Switzerland. 2018. Updated 24 Sept 2018. http://apps.who.int/gho/data/node.country.country-PAK?lang=en. Accessed 14 Oct 2018.
   Google Scholar
• Judicial inquiry tribunal. Batch J093 - the pathology of negligence. 2013. http://lhc.gov.pk/system/files/PIC_drug_inquiry_report.pdf. Accessed 13 Nov 2015.
   Google Scholar
• Nishtar S. Pakistan’s deadly cocktail of substandard drugs. Lancet. 2012;379(9821):1084–1085.
   PubMed Web of Science ®Google Scholar
• Zaidi S, Bigdeli M, Aleem N, Rashidian A. Access to essential medicines in Pakistan: policy and health systems research concerns. PLoS One. 2013;8(5):e63515.
   PubMed Web of Science ®Google Scholar
• Pakistan Pharmaceutical Manufacturers Association. Pakistan’s pharmaceutical industry. 2017. http://www.ppma.org.pk/wp-content/uploads/2017/09/Final-Report-Pharma-Industry_August-10.pdf. Accessed 14 Oct 2018.
   Google Scholar
• Drug Regulatory Authority of Pakistan. Progress report of DRAP for the year 2018, dated 26th Januray , 2019 (Urdu) [press release]. Islamabad, Pakistan, 2019.
   Google Scholar
• Khan AS. No FDA-approved pharmaceutical plant in Pakistan: SBP. DAWN. 24 Nov 2016. https://www.dawn.com/news/1298209. Accessed 17 Oct 2018.
   Google Scholar
• Pacific Pharmaceuticals. Pacific Pharmaceuticals-about us, 2019. http://pacificpharmaceuticals.com/about/. Accessed 23 Apr 2019.
   Google Scholar
• Business Recorder. Pacific Pharmaceuticals obtains accreditation from Britain 13 Aug 2017. https://fp.brecorder.com/2017/08/20170813208313/. Accessed 1 Oct 2018.
   Google Scholar
• Abbassi W. WHO accredits first-ever Pak drug The News 9 Feb 2018. https://www.thenews.com.pk/print/278741-who-accredits-first-ever-pak-drug. Accessed 17 Oct 2018.
   Google Scholar
• Babar Z-U-D, Jamshed SQ, Malik MA, Löfgren H, Gilani A-H. The pharmaceutical industry, intellectual property rights and access to medicines in Pakistan. In: Löfgren H, Williams OD, editors. The new political economy of Pharmaceuticals: production, innovation and TRIPS in the global south. London: Palgrave Macmillan UK; 2013. p. 167–184.
   Google Scholar
• Drug Regulatory Authority of Pakistan. Drug (Licensing, registration and advertising) rules 1976. Islamabad, Pakistan 1976. http://dra.gov.pk/. Accessed 21 Oct 2018.
   Google Scholar
• Drug Regulatory Authority of Pakistan. S.R.O. 272 (I)/2013 (Ammendents in the Drugs, Research Rules, 1978 of the Drug Act, 1976). Islamabad, Pakistan. 2014. http://dra.gov.pk/. Accessed 21 Oct 2018.
   Google Scholar
• Subohi A. Drug research fund lies idle. DAWN. 10 Dec 2007. https://www.dawn.com/news/279566. Accessed 17 Oct 2018.
   Google Scholar
• Tordrup D, Ahmed W, Bukhari KS, Kanavos P. Availability of medical supplies during the 2010 Pakistan floods. Lancet Glob Health. 2013;1(1):e13–e14.
   PubMed Web of Science ®Google Scholar
• Bukhari SK, Qureshi JA, Jooma R, Bile KM, Kazi GN, Zaibi WA, Zafar A. Essential medicines management during emergencies in Pakistan. East Mediterr Health J. 2010;16 Suppl:S106–S113.
   PubMedGoogle Scholar
• Arie S. Contaminated drugs are held responsible for 120 deaths in Pakistan. Br Med J. 2012;344:e951.
   PubMed Web of Science ®Google Scholar
• World Health Organization. QSM/MC/IEA.126: information alert system-alert no. 126 ; contaminated dextromethorphan active pharmaceutical ingredient. Geneva, Switzerland. 2013. http://www.who.int/medicines/publications/drugalerts/Final_Alert_126_Information_on_Dextromethorphan.pdf?ua=1. Accessed 21 Oct 2018.
   Google Scholar
• World Health Organization. A study on the public health and socioeconomic impact of substandard and falsified medical products. Geneva, Switzerland. 2017. http://www.who.int/medicines/regulation/ssffc/publications/Layout-SEstudy-WEB.pdf?ua=1. Accessed 17 Oct 2018.
   Google Scholar
• Seidle L, Khan Z. Federalism and Eighteenth Amendment-challenges and opportunities for transition management in Pakistan. Islamabad, Pakistan. United Nations Development Programme Pakistan; 2012. https://www.undp.org/content/dam/pakistan/docs/Democratic%20Governance/Federalism/UNDP-PK-DGU-Federalism%2018%20Amendment%20Report-2012.pdf. Accessed 2 May 2019.
   Google Scholar
• Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, Gyansa-Lutterodt M, Jing S, Luiza VL, Mbindyo RM, Moller H, Moucheraud C, Pecoul B, Rago L, Rashidian A, Ross-Degnan D, Stephens PN, Teerawattananon Y, T Hoen EF, Wagner AK, Yadav P, Reich MR. Essential medicines for universal health coverage. Lancet. 2017;389(10067):403–476.
   PubMedGoogle Scholar
• Drug Regulatory Authority of Pakistan. Home page. Islamabad, Pakistan. 2018. http://www.dra.gov.pk/. Accessed 21 June 2018.
   Google Scholar
• United States Pharmacopoeia-Promoting Quality of Medicine (USP-PQM). Pakistan adopts international standards for assessing and registering medicines. 2019; Available from: https://www.usp-pqm.org/results/pakistan-adopts-international-standards. Accessed 20 May 2019.
   Google Scholar
• United States Pharmacopoeia-Promoting Quality of Medicine (USP-PQM). Pakistan acts quickly to withdraw contaminated medicines. 2019; Available from: https://www.usp-pqm.org/results/pakistan-acts-quickly-recall-contaminated-medicines. Accessed 20 May 2019.
   Google Scholar
• Maqsood F. Testing of 171,375 samples ensured under campaigns to curb spurious drugs sale. Islamabad, Pakistan. Business Recorder; 2018; https://www.brecorder.com/2018/01/15/392927/testing-of-171375-samples-ensured-under-campaigns-to-curb-spurious-drugs-sale/. Accessed 9 May 2019.
   Google Scholar
• World Health Organization. WHO global benchmarking tool (GBT) for evaluation of national regulatory systems. Geneva, Switzerland. 2019; https://www.who.int/medicines/regulation/benchmarking_tool/en/. Accessed 10 May 2019.
   Google Scholar
• Associated Press of Pakistan (APP). 1600 booked for selling unregistered drugs. 2019; Pakistan Today, Lahore. https://www.pakistantoday.com.pk/2019/03/17/1600-booked-for-selling-unregistered-drugs/. Accessed 9 May 2019.
   Google Scholar
• Zaidi S, Riaz A, Rabbani F, Azam SI, Imran SN, Pradhan NA, Khan GN. Can contracted out health facilities improve access, equity, and quality of maternal and newborn health services? Evidence from Pakistan. Health Res Policy Syst 2015;13 Suppl 1:54.
   Google Scholar
• Drug Regulatory Authority of Pakistan. S.R.O. 307 (I)/2017 (Amendents in the drug (labelling and packaging rules, 1986)). 2017. http://dra.gov.pk/. Accessed 21 Oct 2018.
   Google Scholar
• The Express Tribune (Corresspondent). DRAP to digitize its data in next six months Islamabad. The express tribune; 2019; https://tribune.com.pk/story/1957849/1-drap-digitise-data-six-months/. Accessed 24 April 2019.
   Google Scholar
• World Health Organization. WHO list of prequalified quality control laboratories. Geneva, Switzerland. 2017. Updated 18 Jul 2017. https://extranet.who.int/prequal/sites/default/files/documents/PQ_QCLabsList_23.pdf. Accessed 10 Aug 2017.
   Google Scholar
• Drug Regulatory Authority of Pakistan. The Drug Act 1976. Islamabad, Pakistan. 1976; http://dra.gov.pk/. Accessed 21 Oct 2018.
   Google Scholar
• Kaplan Warren, Boskovic Nikolina, Flanagan Daniel, Lalany Serafina, Lin Chia-Ying, Babar Zaheer-Ud-Din. Pharmaceutical Policy in Countries with Developing Healthcare Systems Synthesis of Country Case Studies. Pharmaceutical Policy in Countries with Developing Healthcare Systems. Switzerland: Springer Nature Publishing; 2017. p. 405–430.
   Google Scholar
• Qadeer E, Fatima R, Fielding K, Qazi F, Moore D, Khan MS. Good quality locally procured drugs can be as effective as internationally quality assured drugs in treating multi-drug resistant tuberculosis. PLoS One. 2015;10(4):e0126099.
   PubMed Web of Science ®Google Scholar
• Dawn. 89 medicines banned. Islamabad. Dawn; 2017. https://www.dawn.com/news/1319290. Accessed 7 May 2019.
   Google Scholar
• Provincial Quality Control Unit Punjab. Drug Safety Alerts-monthly news letters. Lahore, Pakistan. 2018. https://sites.google.com/prod/view/pdcup/divisions/drug-safety-alerts. Accessed 20 June 2018.
   Google Scholar
• Provincial Quality Control Unit Punjab. Drug Safety Punjab Monthly Newsletter-June 2018. Lahore, Pakistan 2018. https://sites.google.com/prod/view/pdcup/downloads?authuser=0. Accessed 20 June 2018.
   Google Scholar
• Binagwaho A, Bate R, Gasana M, Karema C, Mucyo Y, Mwesigye JP, Biziyaremye F, Nutt CT, Wagner CM, Jensen P, Attaran A. Combatting substandard and falsified medicines: a view from Rwanda. PLoS Med. 2013;10:7.
   Web of Science ®Google Scholar
• Gibson L. Drug regulators study global treaty to tackle counterfeit drugs. Br Med J. 2004;328(7438):486.
   PubMedGoogle Scholar
• Ali O. Quality of ceftriaxone in Pakistan: reality and resonance. Pak J Pharm Sci. 2009;22(2):220–229.
   PubMed Web of Science ®Google Scholar
• Government of the Punjab. Press release: Additional chief secretary Punjab visited Drug Testing Laboratory. Lahore. 2017. https://www.punjab.gov.pk/node/2169. Accessed 21 Oct 2018.
   Google Scholar
• Jooma R, Bukhari KS. Pharmaceutical country profile-Pakistan. 2010. http://www.who.int/medicines/areas/coordination/pakistan.pdf. Accessed 20 Oct 2018.
   Google Scholar
• World Health Organization. Seventieth world health assembly update, 29 may 2017. Geneva, Switzerland. 2017. http://www.who.int/mediacentre/news/releases/2017/dementia-immunization-refuguees/en/. Accessed 3 Dec 2018.
   Google Scholar
• World Health Organization. Substandard, spurious, falsely labelled, falsified and counterfeit (SSFFC) medical products. Geneva, Switzerland. . 2016. http://www.who.int/mediacentre/factsheets/fs275/en/. Accessed 20 June 2017.
   Google Scholar
• Ali O. [PhD Thesis] Quality comparison of most prescribing and extensively registered generic medicines in Pakistan. Karachi: Karachi University; 2008.
   Google Scholar
• United States pharmacopoeia. Media reports on medicine quality: focusing on USAID-assisted countries by the promoting the quality of medicines program (USP-PQoM). 2011. http://pdf.usaid.gov/pdf_docs/PA00MRTN.pdf. Accessed 21 Oct 2018.
   Google Scholar
• Sharif F, Anis K. Stopping fake drugs from Pakistan its too late for victims. 2012. http://www.bloomberg.com/news/articles/2012-05-17/stopping-fake-drugs-from-pakistan-is-too-late-for-victims. Accessed 21 Oct 2018.
   Google Scholar
• CNN. Inside the deadly Pakistan counterfeit drug trade. 2015; https://edition.cnn.com/videos/health/2015/08/29/pakistan-counterfeit-drugs.cnn. Accessed 21 Oct 2018.
   Google Scholar
• World Health Organization. QSM/MC/IEA.125-information exchange system-alert No. 125; Contaminated Isotab® (isosorbide mononitrate) incident in Lahore Pakistan Geneva, Switzerland. 2012. http://www.who.int/medicines/publications/drugalerts/DrugSafetyAlert125.pdf?ua=1. Accessed 21 Oct 2018.
   Google Scholar
• Leslie T, Kaur H, Mohammed N, Kolaczinski K, Ord RL, Rowland M. Epidemic of plasmodium falciparum malaria involving substandard antimalarial drugs, Pakistan, 2003. Emerg Infect Dis. 2009;15(11):1753–1759.
   PubMed Web of Science ®Google Scholar
• Lambert PA, Conway BR. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin. J Chemother. 2003;15(4):357–368.
   PubMed Web of Science ®Google Scholar
• Iqbal M, Hakim ST, Hussain A, Mirza Z, Qureshi F, Abdulla EM. Ofloxacin: laboratory evaluation of the antibacterial activity of 34 brands representing 31 manufacturers available in Pakistan. Pak J Med Sci. 2004;20(4):349–356.
   Google Scholar
• Tariq S, Rasheed H, Rasheed MA, Ashraf M. [M.Phil Thesis] Quality evaluation of different brands of ceftriaxone. Lahore: University of Veterinary and Animal Sciences; 2012.
   Google Scholar
• Khan RA. [M.Phil Thesis] Evaluation of thin layer chromatography for field testing of drugs in resource limited countries. Lahore: University of Veterinary and Animal Sciences; 2015.
   Google Scholar
• Junaidi I. Cough syrup recalled from market on DRAP order. DAWN. 10 Apr 2018. https://www.dawn.com/news/1400729. Accessed 21 Oct 2018.
   Google Scholar
• Council of Europe. EDQM’s actions to evaluate impact of impurity in active substance valsartan. Strassbourg, France. 2018. https://www.edqm.eu/sites/default/files/press_release_edqms_actions_to_evaluate_impact_of_impurity_in_active_substance_valsartan_july_2018.pdf. Accessed 3 Dec 2018.
   Google Scholar
• Almuzaini T, Sammons H, Choonara I. Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011). BMJ Open. 2013;3:7.
   Web of Science ®Google Scholar
• Almuzaini T, Sammons H, Choonara I. Quality of medicines in Canada: a retrospective review of risk communication documents (2005-2013). BMJ Open. 2014;4(10):e006088.
   PubMed Web of Science ®Google Scholar
• Bensacon L. Country specific case studies — best practices to combat counterfeit medicines and to protect public health. 2008. https://www.fip.org/files/fip/counterfeit/2008Basel/PS1%20MON%20BESANCON.pdf. Accessed 19 Oct 2018.
   Google Scholar
• Council of Europe. General European OMCL Network (GEON). Strassbourg, France. 2018. https://www.edqm.eu/en/general-european-omcl-network-geon. Accessed 22 Nov 2018.
   Google Scholar
• BioSpectrum Bureau. NOMCoL urge for collaboration between the pharmacopeias and drug regulatory bodies. India. 2015. https://www.biospectrumindia.com/news/73/6763/nomcol-urge-for-collaboration-between-the-pharmacopeias-and-drug-regulatory-bodies.html. Accessed 22 Nov 2018.
   Google Scholar
• Kovacs S, Hawes SE, Maley SN, Mosites E, Wong L, Stergachis A. Technologies for detecting falsified and substandard drugs in low and middle-income countries. PLoS One. 2014;9(3):e90601.
   PubMed Web of Science ®Google Scholar
• Glass BD. Counterfeit drugs and medical devices in developing countries. Res Rep Trop Med. 2014;5:11–22.
   PubMedGoogle Scholar
• Kaur H, Green MD, Hostetler DM, Fernáández FM, Newton PN. Antimalarial drug quality:methods to detect suspect drugs. Therapy. 2010;7:49–57.
   Google Scholar
• Höllein L, Kaale E, Mwalwisi YH, Schulze MH, Holzgrabe U. Routine quality control of medicines in developing countries: analytical challenges, regulatory infrastructures and the prevalence of counterfeit medicines in Tanzania. TrAC. 2016;76:60–70.
   Web of Science ®Google Scholar
• Rasheed H, Höllein L, Holzgrabe U. Future information technology tools for fighting substandard and falsified medicines in low- and middle-income countries. Front Pharmacol. 2018;9:995.
   PubMed Web of Science ®Google Scholar
• Batson JS, Bempong DK, Lukulay PH, Ranieri N, Satzger RD, Verbois L. Assessment of the effectiveness of the CD3+ tool to detect counterfeit and substandard anti-malarials. Malar J. 2016;15(1):119.
   PubMedGoogle Scholar
• Höllein L, Holzgrabe U. Development of simplified HPLC methods for the detection of counterfeit antimalarials in resource-restraint environments. J Pharm Biomed Anal. 2014;98:434–445.
   PubMed Web of Science ®Google Scholar
• Mwalwisi YH, Höllein L, Kaale E, Holzgrabe U. Development of a simple, rapid, and robust liquid chromatographic method for the simultaneous determination of sulfalene, sulfadoxine, and pyrimethamine in tablets. J Pharm Biomed Anal. 2016;129:558–570.
   PubMed Web of Science ®Google Scholar
• Rasheed H, Bukhari KS, Ahmed W, Ahmed N. [Poster presentation] Risk register-a proposal for risk-based post marketing surveillance tool for quality of medicine. 78th FIP World Congress of Pharmacy and Pharmaceutical Sciences; 2nd—6th September 2018 Glasgow, UK.
   Google Scholar
• Veronin MA. Should we have concerns with generic versus brand antimicrobial drugs? A review of issues. J Pharm Health Serv Res. 2011;2(3):135–150.
   Google Scholar
• Hasan SK. Prospects of bioequivalence studies in Pakistan. JDUHS. 2012;6(2):39–41.
   Google Scholar
• Gelbe Liste. Gelbe Liste Indenta. Germany. 2013. https://www.gelbe-liste.de/identa. Accessed 22 Oct 2018.
   Google Scholar
• Hamilton WL, Doyle C, Halliwell-Ewen M, Lambert G. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies. Health Policy Plan. 2016;31(10):1448–1466.
   PubMed Web of Science ®Google Scholar
• Fatokun O. Curbing the circulation of counterfeit medicines in Nigeria. Lancet. 2016;388(10060):2603.
   PubMed Web of Science ®Google Scholar
• Akunyili D. Lessons from Nigeria: the fight aginst counterfeit dugs. Diabetes Voice. 2006;5(3):41–43.
   Google Scholar